Cargando…

The Impact of CYP2D6 Genotyping on Tamoxifen Treatment

Tamoxifen remains a cornerstone of treatment for patients with oestrogen-receptor-positive breast cancer. Tamoxifen efficacy depends on the biotransformation, predominantly via the cytochrome P450 2D6 (CYP2D6) isoform, to the active metabolite endoxifen. Both genetic and environmental (drug-induced)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferraldeschi, Roberta, Newman, William G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Molecular Diversity Preservation International 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4034025/ https://www.ncbi.nlm.nih.gov/pubmed/27713292 http://dx.doi.org/10.3390/ph3041122

Ejemplares similares

CYP2D6 genotype and tamoxifen response
por: Rae, James M, et al.
Publicado: (2005)

CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations
por: Province, M A, et al.
Publicado: (2014)

CYP2D6 genotype affects outcome in postmenopausal breast cancer patients treated with tamoxifen monotherapy
por: Thompson, AM, et al.
Publicado: (2010)

CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer
por: He, Wei, et al.
Publicado: (2020)

Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio
por: Lee, Clara Inkyung, et al.
Publicado: (2020)

Clinical CYP2D6 Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy
por: Mulder, Tessa A. M., et al.
Publicado: (2021)

CYP2D6 Genotype and Tamoxifen Response for Breast Cancer: A Systematic Review and Meta-Analysis
por: Lum, Danny W. K., et al.
Publicado: (2013)

National Prociency Testing Result of CYP2D6*10 Genotyping for Adjuvant Tamoxifen Therapy in China
por: Lin, Guigao, et al.
Publicado: (2016)

Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen
por: Schroth, Werner, et al.
Publicado: (2017)

CYP2D6 Genotype Predicts Plasma Concentrations of Tamoxifen Metabolites in Ethiopian Breast Cancer Patients
por: Ahmed, Jemal Hussien, et al.
Publicado: (2019)

The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer
por: Lammers, L A, et al.
Publicado: (2010)

The ethics of CYP2D6 testing for patients considering tamoxifen
por: Hartman, Anne-Renee, et al.
Publicado: (2007)

Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment
por: Charoenchokthavee, Wanaporn, et al.
Publicado: (2016)

Correction: National Prociency Testing Result of CYP2D6*10 Genotyping for Adjuvant Tamoxifen Therapy in China
Publicado: (2016)

Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial
por: DeCensi, Andrea, et al.
Publicado: (2021)

Relationship between Genotypes Sult1a2 and Cyp2d6 and Tamoxifen Metabolism in Breast Cancer Patients
por: Fernández-Santander, Ana, et al.
Publicado: (2013)

Impacts of Cytochrome P450 2D6 (CYP2D6) Genetic Polymorphism in Tamoxifen Therapy for Breast Cancer
por: Bezerra, Lucas Soares, et al.
Publicado: (2018)

Association of CYP2D6 metabolizer status with mammographic density change in response to tamoxifen treatment
por: Li, Jingmei, et al.
Publicado: (2013)

Application of PBPK Modeling and Virtual Clinical Study Approaches to Predict the Outcomes of CYP2D6 Genotype‐Guided Dosing of Tamoxifen
por: Nakamura, Toshimichi, et al.
Publicado: (2018)

Association between Genetic Polymorphisms of CYP2D6 and Outcomes in Breast Cancer Patients with Tamoxifen Treatment
por: Park, Hyung Seok, et al.
Publicado: (2011)

CYP2D6 testing to predict response to tamoxifen in women with breast cancer: Pharmacogenomic
por: Dahabreh, Issa, et al.
Publicado: (2010)

CYP2D6 variants and the prediction of tamoxifen response in randomized patients: author response
por: Wegman, Pia P, et al.
Publicado: (2005)

CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study
por: Brooks, Jennifer D., et al.
Publicado: (2018)

CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects
por: Dezentjé, V. O., et al.
Publicado: (2015)

Chinese breast cancer patients with CYP2D6*10 mutant genotypes have a better prognosis with toremifene than with tamoxifen
por: Wang, Hongyue, et al.
Publicado: (2021)

Does ethnicity impact CYP2D6 genotype–phenotype relationships?
por: Frederiksen, Trine, et al.
Publicado: (2023)

Methodology for clinical genotyping of CYP2D6 and CYP2C19
por: Carvalho Henriques, Beatriz, et al.
Publicado: (2021)

Interrogation of CYP2D6 Structural Variant Alleles Improves the Correlation Between CYP2D6 Genotype and CYP2D6‐Mediated Metabolic Activity
por: Dalton, Rachel, et al.
Publicado: (2019)

Effects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients
por: Charoenchokthavee, Wanaporn, et al.
Publicado: (2017)

CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer
por: Love, Richard R, et al.
Publicado: (2013)

CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients
por: Sirachainan, Ekaphop, et al.
Publicado: (2012)

The frequencies of CYP2D6 alleles and their impact on clinical outcomes of adjuvant tamoxifen therapy in Syrian breast cancer patients
por: Ismail Al-khalil, Wouroud, et al.
Publicado: (2022)

Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse
por: Sanchez-Spitman, A. B., et al.
Publicado: (2021)

Correction: Methodology for clinical genotyping of CYP2D6 and CYP2C19
por: Henriques, Beatriz Carvalho, et al.
Publicado: (2022)

Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of CYP2D6, CYP2B6, and CYP3A4 genotype
por: Haage, Pernilla, et al.
Publicado: (2018)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism
por: Sanchez Spitman, A. B., et al.
Publicado: (2017)

Application of Mice Humanized for CYP2D6 to the Study of Tamoxifen Metabolism and Drug–Drug Interaction with Antidepressants
por: MacLeod, A. Kenneth, et al.
Publicado: (2017)

Influence of CYP2D6 Polymorphisms on Serum Levels of Tamoxifen Metabolites in Spanish Women with Breast Cancer
por: Zafra-Ceres, Mercedes, et al.
Publicado: (2013)

Pharmacogenomics, CYP2D6, and Tamoxifen: A Survey of the Reasons Sustaining European Clinical Practice Paradigms
por: Reis, Sara S., et al.
Publicado: (2019)

Physiologically Based Pharmacokinetic Modeling of Tamoxifen and its Metabolites in Women of Different CYP2D6 Phenotypes Provides New Insight into the Tamoxifen Mass Balance
por: Dickschen, Kristin, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_pr8fub3j6tov06qf1eqp5see9g